English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/202921
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis

AuthorsDasilva, Noelia; Mayado, Andrea; Teodosio, Cristina; Jara-Acevedo, Maria; Álvarez-Twose, Iván; Matito, Almudena; Sánchez-Muñoz, Laura; Caldas, Carolina; Henriques, Ana; Muñoz-González, J. I.; García-Montero, Andrés ; Sánchez-Gallego, J. Ignacio; Escribano, Luis; Orfao, Alberto
KeywordsHematology
Immunology
Systemic mastocytosis
Monoclonal antibodies
Cell therapy and immunotherapy
Antibody-targetable cell surface membrane proteins
Immuno-phenotyping
Issue Date2019
PublisherMolecular Diversity Preservation International
CitationInternational Journal of Molecular Sciences 20(3): 552 (2019)
AbstractDespite recent therapeutic advances, systemic mastocytosis (SM) remains an incurable disease due to limited complete remission (CR) rates even after novel therapies. To date, no study has evaluated the expression on SM bone marrow mast cells (BMMC) of large panel of cell surface suitable for antibody-targeted therapy. In this study, we analyzed the expression profile of six cell-surface proteins for which antibody-based therapies are available, on BMMC from 166 SM patients vs. 40 controls. Overall, variable patterns of expression for the markers evaluated were observed among SM BMMC. Thus, CD22, CD30, and CD123, while expressed on BMMC from patients within every subtype of SM, showed highly variable patterns with a significant fraction of negative cases among advanced SM (aggressive SM (ASM), ASM with an associated clonal non-MC lineage disease (ASM-AHN) and MC leukemia (MCL)), 36%, 46%, and 39%, respectively. In turn, CD25 and FcεRI were found to be expressed in most cases (89% and 92%) in virtually all BMMC (median: 92% and 95%) from both indolent and advanced SM, but with lower/absent levels in a significant fraction of MC leukemia (MCL) and both in MCL and well-differentiated SM (WDSM) patients, respectively. In contrast, CD33 was the only marker expressed on all BMMC from every SM patient. Thus, CD33 emerges as the best potentially targetable cell-surface membrane marker in SM, particularly in advanced SM.
Description© 2019 by the authors.
Publisher version (URL)http://dx.doi.org/10.3390/ijms20030552
URIhttp://hdl.handle.net/10261/202921
DOI10.3390/ijms20030552
ISSN1661-6596
E-ISSN1422-0067
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
Bone_Dasilva_Freire_Art2019.pdf1,63 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.